Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • thirdmeinvestor thirdmeinvestor Nov 10, 2012 1:02 PM Flag

    GS-7977 + RBV trial (ELECTRON) is a huge failure

    Do you recall that a year ago Pharmasset reported a 100% SVR rate for treatment-naive GT2 and 3 hcv patients treated with PSI-7977 and Ribavirin? Here Gilead reports updated results. As quoted below it is 60-64%, not 100%. GT1 treatment-naive patients also scored 84%,not 98% reported earlier.
    The SVR24 for all groups will be even lower than these SVR12.

    http://finance.yahoo.com/news/gilead-announces-100-percent-sustained-140200057.html

    Population ------------------------------ RESULTS (SVR12)
    GT 1 treatment-naïve --------------------- 84%
    GT 1 null responders ---------------------- 10%
    GT 2/3 treatment-experienced ----------- 68%
    GT 2/3 treatment-naïve (8wks) ---------- 64%
    GT 2/3 treatment-naïve ------------------- 60%

    Their triple combo GS-7977 + GS-5885 + RBV did better for SVR4, but an SVR4 is NOT SVR24 or SVR48.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
VRTX
127.09+3.05(+2.46%)2:19 PMEDT